Sign In
Buy LFMD
$3.50
-0.140 (-3.85%)
At Close: Jul 31, 2026
LifeMD® Announces Entry Into the Behavioral Health Market
08:05am, Monday, 24'th Feb 2025
Expansion to Include Teletherapy, Psychiatry and Medication Management Behavioral Health Offering to be Led by Industry Veteran Julian Cohen NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (N
LifeMD to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
08:00am, Tuesday, 28'th Jan 2025
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the 12th Annual BTIG MedTech, Digital
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
08:00am, Tuesday, 24'th Dec 2024
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend
LifeMD initiated with a Neutral at Mizuho
04:33pm, Tuesday, 03'rd Dec 2024
Mizuho initiated coverage of LifeMD with a Neutral rating and $7 price target. The firm notes that the company has succeeded due to the successful uptake of its virtual 'GLP-1 Weight Management' progr
LifeMD, Inc. (LFMD) Q3 2024 Earnings Call Transcript
09:58am, Saturday, 09'th Nov 2024
LifeMD, Inc. (NASDAQ:LFMD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financia
LifeMD, Inc. (LFMD) Reports Q3 Loss, Lags Revenue Estimates
07:10pm, Thursday, 07'th Nov 2024
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.20 per share a year ago.
LifeMD Reports Third Quarter 2024 Results
04:05pm, Thursday, 07'th Nov 2024
Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65% Record gross margin of 90.6%, up 300 basis points from the year-ago period Adjusted EBITDA increased 33% to
LifeMD Shares Decline Even After the Launch of Testosterone Therapy
12:45pm, Thursday, 24'th Oct 2024
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
04:05pm, Tuesday, 24'th Sep 2024
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividen
LifeMD: Selling WorkSimpli Could Be A Catalyst
03:44pm, Tuesday, 10'th Sep 2024
LifeMD's Q2 2024 earnings were mixed, with management failing to monetize the non-core WorkSimpli asset, leading me to assign it no value. Despite management's over-promising, LifeMD's telehealth and
LifeMD to Participate in Three Investor Conferences During September
04:05pm, Monday, 26'th Aug 2024
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following inv
LifeMD, Inc. (LFMD) Q2 2024 Earnings Call Transcript
11:21pm, Thursday, 08'th Aug 2024
LifeMD, Inc. (NASDAQ:LFMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financial
LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates
07:30pm, Wednesday, 07'th Aug 2024
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.23 per share a year ago.
LifeMD Reports Second Quarter 2024 Results
04:05pm, Wednesday, 07'th Aug 2024
Revenue increased 41% year-over-year to $50.7 million with telehealth revenue up 67% Telehealth achieved standalone profitability one quarter ahead of guidance, with adjusted EBITDA of $820,000 Weight
LifeMD: High Growth GLP-1 Telehealth Play At A Discount
01:07pm, Wednesday, 31'st Jul 2024
LifeMD is positioned as a high-growth telehealth play with a focus on GLP-1 weight management treatments. The company is guiding for 35% revenue growth in 2024. Its core telehealth business is expecte
